以下赞助商和合作伙伴给予BioBay创业投资论坛2010的大力支持。我们衷心感谢这些一流机构和公司对本次论坛的大力协助。如需了解本活动或ChinaBio其他活动的赞助信息,请联系Tom Wu.


Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of initiatives accelerating the globalization of China’s life science industry. ChinaBio has helped China companies raise over $350 million and global life science companies identify over 400 licensing and acquisition opportunities in China.

  • Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees.
  • Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy.
  • Transactions: ChinaBio helps companies secure partnerships and acquisitions and access private and government funding in China.
  • Publishing: ChinaBio® Today is the most widely read online and email newsletter on China’s life science industry.

More information is available at www.ChinaBioLLC.com.

BioBay is located in Dushu Lake Higher Education Town of Suzhou Industrial Park (SIP). Suzhou Industrial Park (SIP) is the largest cooperation program between China and Singapore, and is committed to building a globally competitive high-tech industrial park. BioBay is a key driver for innovation and a key focus of growth at SIP, and is a leader in the development of bio and nanotechnology throughout China.
BioBay has been officially designated as China International Nano-tech Innovation Cluster by Ministry of Science & Technology of PRC, Ministry of Commerce of PRC, and as Jiangsu Province Biopharmaceutical Incubator as well.
BioBay has more than 170 high-tech companies focusing on biotech, pharmaceutical, diagnostics, medical device, CRO, nanotech, and is committed to building a dynamic and interactive innovation cluster for talents and experts. www.biobay.com.cn


Alexandria Real Estate Equities, Inc. (NYSE: ARE), Landlord of Choice to the Life Science Industry®, is the largest owner and preeminent real estate investment trust focused principally on cluster formation through the ownership, operation, management, selective redevelopment, development and acquisition of properties containing office/laboratory space. Alexandria provides high-quality environmentally sustainable real estate, technical infrastructure and services to the broad and diverse life science industry. Client tenants include institutional (universities and independent not-for-profit institutions), pharmaceutical, biopharmaceutical, medical device, product, service, and translational entities, as well as government agencies. Alexandria extends its industry-leading operational platform into Asia with world-class office/laboratory space available for lease at its flagship development in Tianjin, China beginning in late 2009. www.labspace.com

The Balloch Group ("TBG") was established in 2001 by Howard Balloch (Canada's ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008. TBG's professionals are located in Beijing, New York, Shanghai, Hong Kong, Wuhan and Hangzhou serving and investing alongside our clients in mergers and acquisitions, capital markets and direct investment transactions.  www.ballochgroup.com

Broad & Bright is a full service Chinese law firm with international perspectives, providing a broad range of specialized legal services in multiple practice areas for domestic and international clients, with particular expertise and outstanding achievements in cross-border business transactions. Our Chinese and international educated lawyers have long term practice experience at Chinese and international law firms. www.broadbright.com

Foley is a highly regarded, international law firm providing client-focused, industry-specific services that result in high-value legal counsel for our clients. Our practice areas encompass the full range of corporate legal services. With an office located in Shanghai, the attorneys of Foley’s China Practice are well positioned to assist U.S., Asian, and European clients with the complex matters that arise when doing business in or related to Greater China. From IP procurement and technology transfer to M&A due diligence, count on Foley’s experience and our cultural and business connections in China to help you stake you claim. www.foley.com

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.

Mingly China Growth Fund is a private equity fund formed in 2006 to make critical growth and expansion stage investments in China. The Fund Management Team and its Advisors include a collaboration of successful and experienced U.S. and Chinese investment professionals Demonstrated ability to identify sector leaders early and get closely engaged with founders Deep and growing pipeline with active processes to monitor companies, Hands-on operating experience to help transform companies, Global network of contacts to assist with technology, sales and marketing and management expertise, and Both Foreign Currency Fund and RMB Fund to meet the funding needs of various companies. www.mcgf.com.cn

From concept to commercialization and through exit, Morrison & Foerster's global Life Sciences Group is recognized as a leading provider of comprehensive legal services to the life sciences industry and its funding sources. The unique strength of our practice is in our ability to meld hands-on scientific acumen with deep business and legal insight. With offices in Shanghai, Beijing, and Hong Kong, as well as Tokyo, Europe and across the United States, Morrison & Foerster is incomparably positioned to assist life sciences entities around the world. For more information, please visit www.mofo.com.

Pfizer has been operating in China since the early 1980's committed to improving the health of the Chinese people and contributing to China's overall prosperity. Pfizer has built on this legacy by introducing innovative, relevant medicines and investing in doctor and patient educational programs. Furthermore, Pfizer contributes to China's scientific and medical development by including China in our global R&D projects. In recognition of the highly-skilled and talented scientists in China, Pfizer established its China Research and Development Center in Shanghai in 2005. The center is staffed with more than 200 Pfizer colleagues supporting various aspects of Pfizer's global R&D efforts. www.pfizer.com


Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. www.merck.com

OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm, with over $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 100 private companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes approximately 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed’s professionals work together using a collaborative, team-oriented approach to support our portfolio companies, which has earned OrbiMed a reputation as a capital provider of choice for life sciences companies of all stages. OrbiMed has created the first pan-Asia healthcare and life sciences-dedicated venture capital fund, with close to $200M under management. OrbiMed’s headquarters are in New York City and has offices in Shanghai and Mumbai. www.orbimed.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80’000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. www.roche.com


BayHelix is an organization of leaders of Chinese origin in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by invitation only. www.bayhelix.org

BioCentury Publications, Inc., www.biocentury.com provides essential biopharma industry intelligence from five offices in the U.S. and Europe. For more than 18 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship BioCentury, the Bernstein Report on BioBusiness; SciBX: Science-Business eXchange, a translational science joint publishing venture with Nature Publishing Group; and BioCentury Extra, online daily news covering breaking developments BioCentury also markets its BCIQ: BioCentury Online Intelligence, an online business intelligence resource. In September 2010, the company launched BioCentury This Week, the first weekly biotech public affairs TV program to be broadcast in major U.S. television markets, a partnership with the Gannett-owned CBS affiliate W*USA Channel 9 in Washington, D.C. The BioCentury This Week TV show website continuously streams TV content at www.biocentury.com.

Business Wire is a trusted partner to thousands of Health, Medical, Biotech and Pharmaceutical companies and organizations throughout the world, delivering more corporate news releases from more sources to more destinations than any other service. Business Wire's news wire circuits enable you to target your news to select audiences based on your geographic and industry market needs. Business Wire is the only commercial news wire with full-carriage access to all of the world's leading news agencies, including the Associated Press, Agence France-Presse, Dow Jones, Reuters, Jiji Press, Interfax and more. We can send your news to virtually any media market in the world with distribution to more than 150 countries in dozens of local languages. From delivery to audiences in a single city to comprehensive worldwide coverage including translations, Business Wire offers you an easy, one-stop solution. www.businesswire.com

Essinova Life Science TV is an Internet TV channel and community for life sciences, biopharma, medical devices and healthcare services industries. We produce and publish executive interviews, corporate videos, investor pitches, product demos, science and technology visualization, event videos and other multimedia content serving companies and organizations in business for health. Our program brings fresh perspectives, candid insights, unique stories and practical expertise to our viewers. Our creative and broadcast-quality productions showcase innovative ideas, technologies, products and methodologies for our clients more compellingly than any conventional media. We help our clients and members deliver their messages to their desired audience efficiently and cost-effectively, utilizing the power of rich and social media, and leveraging our growing network of partnerships. www.essinova.com

goBalto is a dedicated online drug development partnering site for the pharmaceutical and drug manufacturing industry. Users can identify, evaluate, and manage drug-development partners from around the world. Incorporating the latest in Web 2.0 technologies, goBalto’s platform enables users to distinguish their offerings by adding logos, images, videos, customer testimonials and post referrals from members. More than 7,000 service providers are currently listed. www.goBalto.com

Nature is the world's foremost weekly scientific journal and is the flagship journal for Nature Publishing Group (NPG). Launched in 1869, its original mission statement still leads the Group as we develop publications, explore opportunities arising from new technology and serve a growing audience of readers.NPG publishes journals and online databases across the life, physical and applied sciences and, most recently, clinical medicine. Content encompasses daily news from award-winning journalists, expert opinion and practical methodology, and more high impact research and reviews than any science publisher. Over 30 journals are published in association with prestigious academic societies. www.nature.com


DSM creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com / www.dsm.com.cn

Fidelity Asia Ventures (FAV) is the Asian venture capital arm of FIL Limited, part of the global Fidelity Investments organization. Fidelity Investments is one of the largest mutual fund organizations in the world, managing assets in excess of $1.5 trillion globally.
FAV's mission is to invest in high-quality, high-growth companies broadly in the information technology, healthcare, and consumer sectors in China. FAV has offices in Hong Kong, Beijing, and Shanghai, and a successful track record of investing in leading companies within their respective industries. Current investments and recent exits include: Alibaba (HKSE: 1688), AsiaInfo (NASDAQ: ASIA), Wuxi PharmaTech (NYSE: WX), Hurray! (NASDAQ: HRAY), Linktone (NASDAQ: LTON), Xunlei, and iSoftstone etc. For more information, please visit: www.fidelityasiaventures.com

HBM BioMed China is a specialized venture capital organization dedicated exclusively to life sciences in China. Our main investments will be in China, or in multinational companies that have major operations within China. HBM BioMed China Limited is domiciled in the Cayman Islands and is advised by HBM BioMed China Partners, Hong Kong. HBM BioVentures, an internationally renowned Swiss life science focused holding company is the major shareholder of HBM Biomed China.
With all management team members based in mainland China, we are one of the first foreign venture capital organizations committed to take root in China’s Healthcare Industry. HBM BioMed China strives to generate long-term capital gains via investments in private companies within its target sectors human medicine, biotechnology and medical technology, as well as related industries. HBM BioMed China inherited the successful management model of HBM BioVentures in the hope of promoting China’s Healthcare Industry under its proactive collaboration and cooperation with other Chinese investment companies and cooperation with other Chinese investment companies and institutions. www.hbmbiomedchina.com

Lilly Ventures is the venture capital arm of Eli Lilly and Company, a leading innovation-driven pharmaceutical company. Our primary goal is to facilitate the success of companies in our areas of focus through early to expansion stage investments and value-adding resources.
Lilly Ventures currently has $175 million under management and focuses on three major areas of interest.
Biotechnology: targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a robust pipeline.
Medical Technology: targeting investments in companies focusing on the convergence of pharmaceuticals, devices or diagnostics.
Healthcare IT: targeting investments in start-up companies with innovative network technologies that promise to have a transformational impact on the current pharmaceutical business model.
Our investment approach centers on working with superior management teams to help them realize the financial potential of their ideas. Accordingly, we provide both financial and intellectual resources to accelerate the management teams’ path to success. Our sister fund, Lilly Asian Ventures, was established in 2007 with a geographic focus on the emerging life science businesses of east and south Asia, particularly China and India. www.lilly.com

Mingly China Growth Fund is a private equity fund formed in 2006 to make critical growth and expansion stage investments in China. The Fund Management Team and its Advisors include a collaboration of successful and experienced U.S. and Chinese investment professionals Demonstrated ability to identify sector leaders early and get closely engaged with founders Deep and growing pipeline with active processes to monitor companies, Hands-on operating experience to help transform companies, Global network of contacts to assist with technology, sales and marketing and management expertise, and Both Foreign Currency Fund and RMB Fund to meet the funding needs of various companies. www.mcgf.com.cn

Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. The Chan family founded the Hang Lung Group in Hong Kong in 1960. Morningside engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. Morningside was one of the earliest institutional investors in China's internet industry and in recent years has been a leader in China's emerging biotechnology sector. In China's media sector, Morningside has been active in both outdoor and print media. www.morningside.com.cn


Mustang Ventures is a China-focused venture firm investing in early stage companies that leverage China’s large pool of intellectual talent, burgeoning domestic market, attractive cost structure, and / or proven export capability. Our team combines local investment experience, senior operating leadership and a global network that we leverage to help guide strong entrepreneurs to market success. Mustang’s partners bring together more than 40 years of operating experience and 10 years of investing experience. Our investing team is led by Rob McCormack, who has completed more than 25 investments in private companies while at Trident Capital and Integral Capital Partners, and our operating team by Leonard Liu, who brings more than 30 years experience in the IT industry, building teams and scaling operations at IBM, Acer, Cadence Design Systems, Walker Interactive Systems, ASE and Augmentum – three of which he grew to sales greater than $1 billion. Mustang has a strategic relationship with Trident Capital of Palo Alto, California. We work closely with our portfolio companies in all aspects of company building. From conceptualization of an idea to building a large and profitable business, we rely on our operational and investment expertise to work with entrepreneurs in building world class organizations. www.mustangvc.com


OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm, with over $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 100 private companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes approximately 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed’s professionals work together using a collaborative, team-oriented approach to support our portfolio companies, which has earned OrbiMed a reputation as a capital provider of choice for life sciences companies of all stages. OrbiMed has created the first pan-Asia healthcare and life sciences-dedicated venture capital fund, with close to $200M under management. OrbiMed’s headquarters are in New York City and has offices in Shanghai and Mumbai. www.orbimed.com

In Chinese, “Qiming” literally means starting point and light, purporting the beginning of a new day. Headquartered in Shanghai, Qiming Ventures is dedicated to become a leading venture capital enterprise, devoting to the risk investment to Chinese scientific fields along with its American Ignition Partners. Currently, Qiming Ventures has over $500 million under management; together with its affiliate Ignition Partners, they manage more than $2.5 billion venture capital funds globally. Investment team of Qiming Ventures has rich expertise, enterprise operation practices and investment management experience at home and abroad; Qiming Ventures provides finance to experienced entrepreneurs and businesses with stable profit models, hoping to assist Chinese entrepreneurs to create enterprises with business volumes of billion US $.

Qiming Ventures is active to invest in the following sectors:

  • HealthCare
  • Media and Internet
  • Information Technology
  • Consumer and Retail
  • Clean Energy



WI Harper Group works with entrepreneurs who target growth opportunities in Greater China as a key objective for their business. WI Harper pioneered the concept of building a business bridge across the Pacific Ocean for early stage IT and life sciences companies. Since 1996, we have backed over 90 emerging companies in China, Taiwan and the United States, resulting in 15 IPOs and a number of M&A transactions. Our investment professionals in Beijing, San Francisco and Taipei manage over $400M in assets. WI Harper currently manages six funds totaling over US$400 million from its headquarters in San Francisco and branch offices in Beijing, Taipei, and Singapore. WI Harper's portfolio includes over 90 companies in high-growth areas of information technology and life sciences. WI Harper's list of successful portfolio companies currently include examples such as Focus Media (NASDAQ: FMCN), ISSI (NASDAQ: ISSI), iKang, DivX (NASDAQ: DIVX), Commerce One, Bridge Pharmaceutical, Cardiva Medical, PC Home, Kuro, Silicon Motion (NASDAQ: SIMO), Beijing Xinwei, Verisilicon, China Broad Media, MAXTHON, HomeE, Panorama Stock, 3G Portal, Mapbar and Laszlo etc. The firm's previous investments include with companies such as Creative Technology, CommerceOne, Intraware, S3, ISSI and many other public companies. www.wiharper.com


BIOCOM is a leading biotechnology industry association with over 550 leading life science companies from Southern California as members. BIOCOM's initiatives focus on capital formation, public policy, resource development and scientific discovery and development. They have recently launched a special program to educate and connect U.S.-based life science companies with low cost resources and services available in China. www.biocom.org

Beijing Pharma and Biotech Center (BPBC) is the principal health research agency of the Beijing Local Government; it is a component of Beijing Municipal Commission for Science and Technology (BMCST). Established in 1996 and initially function as the development and implementation of Beijing Government Grants Policy, BPBC serves as the focal point for advisory industrial policy, mandatory project management for government and international bridge between Chinese Biotech & Pharmaceutical Industry and the rest of the world. BPBC is composed of five divisions: Project Management, Strategy Study, Business Liaison and International Affairs, General Administration and Financial Management Divisions. www.newlife.org.cn

Chinese-American BioPharmaceutical Society (CABS) is a not-for-profit, non-political, non-religious professional organization headquartered in San Francisco, California. With the rapid development of bio/pharmaceutical industry in China, more and more people, regardless of their ethnic backgrounds, are looking toward China for business and scientific opportunities. Recognizing this trend, CABS was established not only to educate the public with the progress in biotech and pharmaceutical fields, but also to serve the Bio/Pharmaceutical professionals who are either with Chinese heritage or with professional interests in China. The majority of CABS members are Chinese scientists, entrepreneurs and students/postdocs in biomedical sciences, working in San Francisco Bay Area bio/pharmaceutical industries, universities, and research institutes. The CABS membership is open to the public. www.cabsweb.org

The Chinese Biopharmaceutical Association (CBA) is a non-profit organization made up of professionals who have an interest in bio-pharmaceutical research and/or technology development. CBA was established in 1995 and its headquarters are located in the State of Maryland, which is adjacent to the U.S. capital city of Washington D.C. The majority of CBA members are Chinese scientists, researchers, or professors. They work in government agencies, universities, research institutes as well as in the biotechnology and pharmaceutical industries. Some are conducting pioneering research with the National Institutes of Health (NIH), whereas others are directly involved in the government regulatory process as officers of the Food and Drug Administration (FDA) or in the field of intellectual property as patent attorneys or as patent examiners with the Patent and Trademark Office (PTO). www.cba-usa.org

Guangzhou Biotechnology Center (namely Biomedical work group of Guangzhou Municipal Government) under the jurisdiction of the Biotechnology Steering Group and the Sciences &Technology Bureau of Guangzhou Municipal Government is a service agency specializing in biotechnology and medicine industry. Its key missions are to develop the biotechnology and medicine industry of Guangzhou and to accelerate the transfer of S&T achievements and parallel cooperation and exchange. www.gzbio.net

Hong Kong Science and Technology Parks Corporation (HKSTP) is a statutory body set up by the Government of the Hong Kong SAR to promote and facilitate the transformation of Hong Kong into Asia’s hub for technology innovation. The Corporation supports a number of technology industries engaging in cutting-edge research and development, including the Life Science and Biotechnology industries, and offers a comprehensive range of facilities and services to address the needs of companies at various stages of development. www.hkstp.org

Lychee Group is a media company specializing in the organization of high-end business-to-business events for China's life sciences industry. We have launched some of the highest-profile events in China including, “CHINATRIALS: Global Clinical Development Summit” and “China Healthcare Investment Conference,” both the largest events in China of their kind. Our mission is simple: create the best, most innovative events to provide our attendees with the latest business information and the greatest opportunity to network with peers and new potential business partners. www.lycheegroup.com

Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA) is a 501(C) (3) nonprofit organization founded in early 2002 by professionals and scholars from local Chinese community in San Diego. We invite all scholars, students and professionals with any origin who are working in, engaged in, or interested in the biotech and pharmaceutical industry to join us as members of SABPA. www.sabpa.org

The Sino-American Pharmaceutical Professionals Association (SAPA) was founded in 1993 as a non-profit organization with its headquarters in the Greater New York area (NJ/NY/CT). SAPA has grown rapidly to become one of the most active and well-recognized professional organizations in the United States with over 4000 members. SAPA's missions are to facilitate the advancement of pharmaceutical science and biotechnology, to contribute to public health education, to foster personal and professional career development, and to promote scientific exchange and business cooperation between the USA and China. In addition to the Greater New York area, SAPA has established regional chapters in New England (SAPA-NE), Greater Philadelphia (SAPA-GP) and West Coast (SAPA-WEST), as well as Shanghai Club (SAPA-Shanghai). www.sapaweb.org


China is already the fastest growing market in the world for pharmaceuticals. Now, after billions of dollars of government and private investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today focuses exclusively on the rapidly evolving biotech industry in China. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China biotech companies and industry events, as well as global issues affecting the China market. www.chinabiotoday.com

Bioon is the leading life science portal in China. And professional registered members have more than 500 thousand; special 70% members are the master's -and doctoral qualifications. Our enterprises’ customers are more than 11 thousand, such as Invitrogen, Promega, Qiagen, Sigma, Pall. As the leading service- provider in China, we are committed to enhance the competition of our customers in life sciences. The following pipelines are our mature businesses: (1) www.bioon.com commitment to the field of life sciences media and brand promotion; (2) www.bioon.com.cn focused on our customers’ products -promotion, display and rankings, such as equipments, consumables, reagents and antibodies; Addition, we collected and sorted the serial of databases -including China lab database, professor database and region -based registered members database. These databases are the strong support and tool for customers marketing activity and marketing survey & analysis. Now, Bioon.com has become the preferred options to life sciences’ customers for professional seminar & training, targeting product promotion, brand -improvement and marketing survey & analysis. of professional customers in China. www.bioon.com

CRO Asia © is a premium online media platform targeting pharmaceutical outsourcing industry namely contract research and manufacturing organizations based in Asia-Pacific regions. Our objective is to forge potential collaborations and strategic partnerships by using our unique marketing tools and quality communication services. For more information, please visit us at www.croasia.net.

Interfax China is a member of the Interfax International Information Group. Interfax Group provides news and other information products that are essential for decision-makers in politics and business. Since early 1990s, Interfax has been the main provider of up-to-date news from Russia and countries of the former Soviet Union. We are the most frequently quoted source of information on the region. Over the past few years, Interfax has also become a leading provider of political and business news from China and emerging markets of Central Europe. www.interfax.cn

《医药经理人》(月刊)2008年12月正式创刊,以资深医药传媒人为基础团队,定位为“医药行业的新闻与资源中心”,核心读者群为医药企业经 营者、投资者、医药行业监管与服务机构。主办单位是中国医药企业管理协会和卓信医学传媒集团。在内容制作上,把求实放在第一位,打通整个产业链条,挖掘药 企经营者的经验与焦虑,战略与执行,成长与使命。形成中国医药行业最丰富的企业成长案例库。将国际视野和本土智慧有机结合,开放而聚焦,把对医药产业最丰 富和深刻的理解带给读者,建立医药产业媒体新话语。把医药研发新产品、生产流通、产业监管与服务机构、资本等资讯第一时间放到行业高端媒体平台,形成信息 对称,发现价值,共同成长。我们的愿景是每一位医药从业者手上都有一本《医药经理人》,我们现在要做的是每一期杂志都能给读者创造出一种兴奋感。www.he-cn.com

PharmAsiaNews.com is an online portal providing news and analysis on regulatory, legal and financial developments affecting pharmaceutical, biologics and medical device manufacturers doing business in China, India, Japan and other nations of the Pacific Rim. PharmAsiaNews.com leverages the editorial excellence of "The Pink Sheet" -- the leading information source for the U.S. pharmaceutical industry since 1939. Subscribers get original on-the-ground reporting from news bureaus across Asia, guest columns, exclusive interviews, news summaries, English translation summaries of Chinese- and Japanese-language news, and aggregated content from around the globe. Free 30-day trial. www.PharmAsiaNews.com

Pharma Connections Worldwide® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities among industry professionals responsible for making key decisions in a global marketplace. www.pharmaconnections.com


Tom Wu
ChinaBio® LLC
Tel: +86 21 5137 0751 分机 15
Fax: +86 21 5137 1368
From USA: +1 858 926 4566 分机 15



赞助商 & 合作伙伴